KIORA PHARMACEUTICALS, INC.: income tax expense or benefit
Income tax expense or benefit for KIORA PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All KIORA PHARMACEUTICALS, INC. financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -1,282,149 | USD | 2026-03-25 | 10-K · 0001372514-26-000024 |
| 2024-01-01 | 2024-12-31 | 2,065,005 | USD | 2026-03-25 | 10-K · 0001372514-26-000024 |
| 2023-01-01 | 2023-12-31 | 90,319 | USD | 2025-03-25 | 10-K · 0001372514-25-000012 |
| 2022-01-01 | 2022-12-31 | -113,010 | USD | 2024-03-25 | 10-K · 0001372514-24-000026 |
| 2021-01-01 | 2021-12-31 | -192,603 | USD | 2023-03-23 | 10-K · 0001372514-23-000050 |
| 2020-01-01 | 2020-12-31 | 12,055 | USD | 2022-07-07 | 10-K/A · 0001410578-22-001931 |
| 2019-01-01 | 2019-12-31 | 95,396 | USD | 2021-03-25 | 10-K · 0001104659-21-041515 |
| 2018-01-01 | 2018-12-31 | 86,045 | USD | 2020-03-04 | 10-K · 0001104659-20-029162 |
| 2017-01-01 | 2017-12-31 | -1,341,973 | USD | 2019-03-01 | 10-K · 0001144204-19-011634 |
| 2016-01-01 | 2016-12-31 | 0 | USD | 2018-03-02 | 10-K · 0001144204-18-012542 |
Related financial histories
- KIORA PHARMACEUTICALS, INC.: total assets
- KIORA PHARMACEUTICALS, INC.: total liabilities
- KIORA PHARMACEUTICALS, INC.: stockholders equity
- KIORA PHARMACEUTICALS, INC.: cash and cash equivalents
- KIORA PHARMACEUTICALS, INC.: net income or loss
- KIORA PHARMACEUTICALS, INC.: operating cash flow
- KIORA PHARMACEUTICALS, INC.: capital expenditure payments
- KIORA PHARMACEUTICALS, INC.: revenue
- KIORA PHARMACEUTICALS, INC.: contract revenue excluding tax
- KIORA PHARMACEUTICALS, INC.: financing cash flow
- KIORA PHARMACEUTICALS, INC.: investing cash flow
- KIORA PHARMACEUTICALS, INC.: retained earnings or deficit
- KIORA PHARMACEUTICALS, INC.: basic weighted-average shares
- KIORA PHARMACEUTICALS, INC.: diluted weighted-average shares
- KIORA PHARMACEUTICALS, INC.: basic earnings per share
- KIORA PHARMACEUTICALS, INC.: diluted earnings per share
- KIORA PHARMACEUTICALS, INC.: net property, plant and equipment
- KIORA PHARMACEUTICALS, INC.: share-based compensation expense
- KIORA PHARMACEUTICALS, INC.: operating income or loss
- KIORA PHARMACEUTICALS, INC.: current assets
- KIORA PHARMACEUTICALS, INC.: interest expense
- KIORA PHARMACEUTICALS, INC.: current liabilities
- KIORA PHARMACEUTICALS, INC.: current accounts payable
- KIORA PHARMACEUTICALS, INC.: goodwill carrying amount
- KIORA PHARMACEUTICALS, INC.: net finite-lived intangible assets
- KIORA PHARMACEUTICALS, INC.: net current accounts receivable
- KIORA PHARMACEUTICALS, INC.: operating expenses
- KIORA PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- KIORA PHARMACEUTICALS, INC. / CIK 0001372514
- Captured
- 2026-09-20T07:57:09.611Z
- SEC response SHA-256
3c8ad9197d1b760a7f418642919ba51ce1343d392d1a4d1fce0d72996117d019
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001372514.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))